Stealth Biotherapeutics Presents At NIH Acute Kidney Injury Outcomes Meeting: Bendavia Clinical Results Highlighted During Industry Panel

alth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today announced interim Phase 2 clinical results with Bendavia in its cardio-renal program. Bendavia’s results in an acute kidney injury (AKI) trial were featured during the Industry Panel at the first National Institutes of Health AKI Outcomes Meeting in Bethesda, Maryland.

Help employers find you! Check out all the jobs and post your resume.